Profile of ospemifene in the breast

Reproductive Sciences

Volumn 20, Issue 10, 2013, Pages 1130-1136

  Berga, Sarah L ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

breast; ospemifene; selective estrogen receptor modulator; vaginal atrophy

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; OSPEMIFENE; RALOXIFENE; TOREMIFENE;

BINDING AFFINITY; BONE; BRAIN; BRAIN HEMORRHAGE; BREAST; BREAST CALCIFICATION; BREAST CANCER; BREAST EXAMINATION; BREAST TUMOR; CANCER INHIBITION; DEEP VEIN THROMBOSIS; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EMBASE; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; HEART; HOT FLUSH; HUMAN; MAMMOGRAPHY; MEDLINE; NONHUMAN; PALPATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; VAGINA; VENOUS THROMBOEMBOLISM;

BREAST; OSPEMIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VAGINAL ATROPHY;

ANIMALS; BREAST; DYSPAREUNIA; FEMALE; HUMANS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VAGINA; VULVA;

EID: 84883682296     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113497290     Document Type: Review

References (44)

1. Nath A, Sitruk-Ware R. Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric. 2009 ; 12 (3). 188-205
2. Pickar JH, MacNeil T, Ohleth K. SERMs: progress and future perspectives. Maturitas. 2010 ; 67 (2). 129-138
3. Obiorah I, Jordan VC. Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas. 2011 ; 70 (4). 315-321
4. Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause. 2012 ; 19 (1). 109-117
5. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009 ; 6 (8). 2133-2142
6. Sturdee DW, Panay N. International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010 ; 13 (6). 509-522
7. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med. 2005 ; 2 (suppl 3). 154-165
8. Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005 ; 7 (6). R881 - R889
9. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001 ; 77 (4-5). 271-279
10. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005 ; 97 (3). 230-240
11. McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010 ; 6 (6). 773-779
12. Gennari L. Ospemifene hormos. Curr Opin Investig Drugs. 2004 ; 5 (4). 448-455
13. Bachmann GA, Komi JO. Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010 ; 17 (3). 480-486
14. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.. Endocrinology. 2000 ; 141 (2). 809-820
15. Simon J, Lin V, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013 ; 20 (4). 418-427
16. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009 ; 12 (2). 91-105
17. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012 ; 120 (3). 595-603
18. Kingsberg S, Wysocki S, Magnus L, Krychman M J Sex Med. 2013: 1790-1799.
19. Wurz GT, Soe LH, DeGregorio MW Maturitas. 2013: 220-225.
20. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American menopause society. Menopause. 2007 ; 14 (3 pt 1). 355-369
21. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol. 2006 ; 20 (3). 534-543
22. Zwart W, de Leeuw R., Rondaij M, Neefjes J, Mancini MA, Michalides R. The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci. 2010 ; 123 (pt 8). 1253-1261
23. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007 ; 25 (36). 5815-5824
24. Wend K, Wend P, Krum SA. Tissue-specific effects of loss of estrogen during menopause and aging. Front Endocrinol (Lausanne). 2012 ; 3: 19
25. Wardell SE, Kazmin D, McDonnell DP. transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol. 2012 ; 26 (7). 1235-1248
26. Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 2004 ; 6 (1). 39-52
27. Speirs V, Skliris GP, Burdall SE, Carder PJ. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol. 2002 ; 55 (5). 371-374
28. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011 ; 10 (10). 778-792
29. Taylor HS. Designing the ideal selective estrogen receptor modulator - an achievable goal?. Menopause. 2009 ; 16 (3). 609-615
30. Portman DJ, Bachmann G, Simon J. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. The Ospemifene Study Group 2013 ; 20 (6). 623-630
31. Bachmann G, Goldstein S, Lin V, Simon J, Portman D, Phelps M. Efficacy of ospemifene when used in the treatment of vulvar and vaginal atrophy for up to 52 weeks in postmenopausal women. Climacteric. 2011 ; 14 (suppl 1). 92
32. Simon J, Bachmann G, Goldstein S, Lin V, Portman D, Phelps M. Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women (abstract). Climacteric. 2011 ; 14 (suppl 1). 87
33. Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012 ; 19 (1). 96-103
34. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003 ; 42 (4). 361-372
35. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 1997 ; 57 (15). 3071-3078
36. Simon J. Efficacy and safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women (abstract). Menopause. 2012 ; 19 (12). 1397-1398
37. Florham Park, NJ: Shionogi Inc ; 2013 :
38. Ibe C, Simon JA. Vulvovaginal atrophy: current and future therapies (CME). J Sex Med. 2010 ; 7 (3). 1042-1050
39. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998 ; 351 (9114). 1451-1467
40. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA... 1999 ; 281 (23). 2189-2197
41. Indianapolis, IN: Eli Lilly and Company ; 2011 :
42. Wilmington, DE: AstraZeneca ; 2002 :
43. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010 ; 362 (8). 686-696
44. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005 ; 146 (9). 3999-4008